Treatment of severe hyperlipidemia: six years' experience with low-density lipoprotein apheresis.
In total, 30 patients suffering from familial hypercholesterolemia, resistant to diet and lipid-lowering drugs, were treated for up to 6 years (3.6 + or - 1.6; range, 0.2-6.8 years) with low-density lipoprotein (LDL) apheresis. Three different systems were used; the dextran sulfate adsorption system (Kaneka) for 27 of 30 patients, the immunoadsorption system from Baxter for 2 of 30 patients, and the immunoadsorption system with special lipoprotein(a) (Lp[a]) columns from Lipopak for one patient. Prior to the LDL apheresis, 23 of 30 patients suffered from coronary heart disease. Twenty of 23 patients suffered intermittently from symptoms of angina, excertional dyspnea, and claudication. With LDL apheresis, reductions of 47% for total cholesterol, 49% for LDL, 26% for Lp(a), and 40% for triglycerides were reached. Severe side effects such as shock or allergic reactions were very rare (0.55%). In the course of treatment with LDL apheresis, an improvement in general well-being and increased performance were experienced in 27 of 30 patients. A reduction of nitrate medication between 60 and 100% was observed in 17 of 23 patients. The present data clearly demonstrate that treatment with LDL apheresis in patients suffering from severe familial hyperlipidemia, resistant to maximum conservative therapy, is very effective and safe even over long periods of time.
Bambauer
R
R
University of Saarland, Homburg, Germany.
Schiel
R
R
Latza
R
R
Klinkmann
J
J
D000327:Adsorption; D000328:Adult; D000368:Aged; D001055:Apolipoproteins B / Q000097:blood / Q000302:isolation & purification; D008076:Cholesterol, HDL / Q000097:blood / Q000302:isolation & purification*; D008078:Cholesterol, LDL / Q000097:blood / Q000302:isolation & purification*; D003327:Coronary Disease / Q000503:physiopathology / Q000628:therapy; D016264:Dextran Sulfate / Q000737:chemistry / Q000378:metabolism; D005260:Female; D005340:Fibrinogen / Q000302:isolation & purification; D006801:Humans; D006938:Hyperlipoproteinemia Type II / Q000178:diet therapy / Q000188:drug therapy / Q000628:therapy*; D007164:Immunosorbents; D017270:Lipoprotein(a) / Q000097:blood / Q000302:isolation & purification; D008137:Longitudinal Studies; D008297:Male; D008875:Middle Aged; D010956:Plasmapheresis / Q000009:adverse effects; D014280:Triglycerides / Q000097:blood / Q000302:isolation & purification
D001055:Apolipoproteins B; D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D007164:Immunosorbents; D017270:Lipoprotein(a); D014280:Triglycerides; D005340:Fibrinogen; D016264:Dextran Sulfate